This trial is testing a new combination drug treatment for women with ovarian cancer that has stopped responding to other treatments.
3 Primary · 10 Secondary · Reporting Duration: 30 months
Experimental Treatment
138 Total Participants · 1 Treatment Group
Primary Treatment: ZN-c3 · No Placebo Group · Phase 1 & 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: